Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Gain Therapeutics, retaining the price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Gain Therapeutics’ promising developments and strategic advancements. The company has successfully completed enrollment for its Phase 1b trial of GT-02287 in Parkinson’s disease ahead of schedule, which is a significant milestone. This early completion allows for the anticipation of biomarker data by the fourth quarter of 2025, potentially providing proof of concept for the drug’s efficacy.
GT-02287, an allosteric modulator, has shown encouraging preclinical results, including enhanced enzyme activity and neuroprotection, which supports its potential as a disease-modifying treatment. Furthermore, Gain Therapeutics is well-funded through the Phase 1b data release, which is crucial for its ongoing development plans. The valuation model incorporates a 70% revenue risk adjustment and a 30% discount rate, reflecting the clinical trial risks and development stage, leading to a favorable 12-month price target.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $12.00 price target.